Modulation of virus-induced innateimmunity and type 1 diabetes by IL-1 blockade

Innate Immunity

Volumn 20, Issue 6, 2014, Pages 574-584

  Hara, Naoko ^a   Alkanani, Aimon K ^a   Dinarello, Charles A ^b   Zipris, Danny ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Gut bacteria; IL 1 receptor antagonist; Inflammation; Innate immunity; Kilham rat virus; Type 1 diabetes

Indexed keywords

INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; COMPLEMENTARY DNA; INTERLEUKIN 23; RNA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNOMODULATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LYMPH NODE; MALE; MICROBIAL COMMUNITY; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SPLEEN; T LYMPHOCYTE; VIRAL CLEARANCE; ANIMAL; COMPLICATION; CYTOLOGY; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; LEWIS RAT; METABOLISM; MICROFLORA; PARVOVIRIDAE; PARVOVIRUS INFECTION; VIRUS INDUCED INNATE IMMUNITY;

ANIMALS; DIABETES MELLITUS, TYPE 1; FEMALE; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-12; LYMPH NODES; MALE; MICROBIOTA; PARVOVIRIDAE INFECTIONS; PARVOVIRUS; RATS; RATS, INBRED LEW; SPLEEN; T-LYMPHOCYTES;

EID: 84907050797     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425913502242     Document Type: Article

References (46)

1. Schranz DB and Lernmark A. Immunology in diabetes: an update. Diabetes Metab Rev 1998; 14: 3-29.
2. Seissler J, de Sonnaville JJ, Morgenthaler NG, Steinbrenner H, Glawe D, Khoo-Morgenthaler UY, et al. Immunological heterogeneity in type I diabetes: presence of distinct autoAb patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998; 41: 891-897.
3. Srikanta S, Ganda OP, Jackson RA, Gleason RE, Kaldany A, Garovoy MR, et al. Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction. Ann Intern Med 1983; 99: 320-326.
4. Gianani R and Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev 2005; 204: 232-249.
5. Jun HS and Yoon JW. The role of viruses in Type I diabetes: two distinct cellular and molecular pathogenic mechanisms of virusinduced diabetes in animals. Diabetologia 2001; 44: 271-285.
6. Jun HS and Yoon JW. A new took at viruses in type 1 diabetes. Diabetes Metab Res Rev 2003; 19: 8-31.
7. Soltesz G, Patterson CC and Dahlquist G. Worldwide childhood type 1 diabetes incidence-what can we learn from epidemiology? Pediatr Diabetes 2007; 8(Suppl. 6): 6-14.
8. Mordes JP, Guberski DL, Leif JH, Woda BA, Flanagan JF, Greiner DL, et al. LEW.1WR1 rats develop autoimmune diabetes spontaneously and in response to environmental perturbation. Diabetes 2005; 54: 2727-2733.
9. Zipris D. Epidemiology of type 1 diabetes and what animal models teach us about the role of viruses in disease mechanisms. Clin Immunol 2009; 131: 11-23.
10. Ellerman KE, Richards CA, Guberski DL, Shek WR and Like AA. Kilham rat triggers T-cell-dependent autoimmune diabetes in multiple strains of rat. Diabetes 1996; 45: 557-562.
11. Zipris D. Innate immunity and its role in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2008; 15: 326-331.
12. Zipris D. Toll-like receptors and type 1 diabetes. Adv Exp Med Biol 2010; 654: 585-610.
13. Londono P, Komura A, Hara N and Zipris D. Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes. Clin Immunol 2010; 135: 401-411.
14. Hara N, Alkanani AK, Ir D, Robertson CE, Wagner BD, Frank DN, et al. Prevention of virus-induced type 1 diabetes with antibiotic therapy. J Immunol 2012; 189: 3805-3814.
15. Mandrup-Poulsen T, Pickersgill L and Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010; 6: 158-166.
16. Nicoletti F, di Marcou R, Barcelliniu W, Magro G, Schorlemmeru HU, Kurrleu R, et al. Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. Eur J Immunol 1994; 24: 1843-1847.
17. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo- controlled trials. Lancet 2013; 381: 1905-1915.
18. Zipris D, Hillebrands JL, Welsh RM, Rozing J, Xie JX, Mordes JP, et al. Infections that induce autoimmune diabetes in BBDR rats modulate CD4+CD25+ T cell populations. J Immunol 2003; 170: 3592-3602.
19. Guberski DL, Thomas VA, Shek WR, Like AA, Handler ES, Rossini AA, et al. Induction of type I diabetes by Kilhams rat virus in diabetes-resistant BB/Wor rats. Science 1991; 254: 1010-1013.
20. Valladares R, Sankar D, Li N, Williams E, Lai KK, Abdelgeliel AS, et al. Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS One 2010; 5: e10507.
21. Wolter TR, Wong R, Sarkar SA and Zipris D. DNA microarray analysis for the identification of innate immune pathways implicated in virus-induced autoimmune diabetes. Clin Immunol 2009; 132: 103-115.
22. Hara N, Alkanani AK, Ir D, Robertson CE, Wagner BD, Frank DN, et al. The role of the intestinal microbiota in type 1 diabetes. Clin Immunol 2013; 146: 112-119.
23. Zipris D, Lien E, Xie JX, Greiner DL, Mordes JP and Rossini AA. TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J Immunol 2005; 174: 131-142.
24. Ball-Goodrich LJ, Paturzo FX, Johnson EA, Steger K and Jacoby RO. Immune responses to the major capsid protein during parvovirus infection of rats. J Virol 2002; 76: 10044-10049.
25. Hirt B. Molecular biology of autonomous parvoviruses. Contrib Microbiol 2000; 4: 163-177.
26. Gabay C, Lamacchia C and Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010; 6: 232-241.
27. Coccia M, Harrison OJ, Schiering C, Asquith MJ, Becher B, Powrie F, et al. IL-1b mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells. J Exp Med 2012; 209: 1595-1609.
28. Dinarello CA, Simon A and Van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11: 633-652.
29. Dinarello CA. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr Opin Immunol 1991; 3: 941-948.
30. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-550.
31. Alkanani AK, Rewers M, Dong F, Waugh K, Gottlieb PA and Zipris D. Dysregulated Toll-like receptor-induced interleukin-1? and interleukin-6 responses in subjects at risk for the development of type 1 diabetes. Diabetes 2012; 61: 2525-2533.
32. Meyers A, Shah R, Gottlieb P and Zipris D. Altered toll-like receptor signaling pathways in human type 1 diabetes. J Mol Med 2010; 88: 1221-1231.
33. Wang X, Jia S, Geoffrey R, Alemzadeh R, Ghosh S and Hessner MJ. Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. J Immunol 2008; 180: 1929-1937.
34. Ablamunits V, Henegariu O, Hansen JB, Opare-Addo L, Preston-Hurlburt P, Santamaria P, et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012; 61: 145-154.
35. Thomas HE, Irawaty W, Darwiche R, Brodnicki TC, Santamaria P, Allison J, et al. IL-1 receptor deficiency slows progression to diabetes in the NOD mouse. Diabetes 2004; 53: 113-121.
36. Schott WH, Haskell BD, Tse HM, Milton MJ, Piganelli JD, Choisy-Rossi CM, et al. Caspase-1 Is not required for type 1 diabetes in the NOD mouse. Diabetes 2004; 53: 99-104.
37. Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T, et al. Transcription factors NF-IL6 and NFkappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. PNAS 1993; 90: 10193-10197.
38. Xu Z, Xiao SB, Xu P, Xie Q, Cao L, Wang D, et al. miR-365, a novel negative regulator of interleukin-6 gene expression, is cooperatively regulated by Sp1 and NF-kB. J Biol Chem 2011; 286: 21401-21412.
39. Deon D, Ahmed S, Tai K, Scaletta N, Herrero C, Lee IH, et al. Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. J Immunol 2001; 167: 5395-5403.
40. Lien E and Zipris D. The role of toll-like receptor pathways in the mechanism of type 1 diabetes. Curr Mol Med 2009; 9: 52-68.
41. Diehl S and Rinccon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 2002; 39: 531-536.
42. Hirsch E, Irikura VM, Paul SM and Hirsh D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. PNAS 1996; 93: 11008-11013.
43. Boni-Schnetzler M, Boller S, Debray S, Bouzakri K, Meier DT, Prazak R, et al. Free Fatty acids induce a pro-inflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009; 150: 5218-5229.
44. Eizirik DL and Mandrup-Poulsen T. A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44: 2115-2133.
45. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39: 1005-1029.
46. Pickersgill LMS and Mandrup-Poulsen TR. The anti-interleukin- 1 in type 1 diabetes action trial-background and rationale. Diabetes Metab Res Rev 2009; 25: 321-324.